TC BURSA ULUDAĞ ÜNİVERSİTESİ TIP FAKÜLTESİ GÖĞÜS HASTALIKLARI ANABİLİM
DALI İDİYOPATİK PULMONER FİBROZİSLİ H Page 1 TC BURSA ULUDAĞ ÜNİVERSİTESİ …

Chronic Interstitial Lung Diseases (ILD) are characterised by the interstitial involvement of
the lungs, often resulting in the aberrant deposition of fibrotic tissue which causes …

Recently a debate has emerged regarding the optimal endpoint for phase 3 clinical trials in
idiopathic pulmonary fibrosis (IPF). IPF clinical trials, including the pirfenidone and …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a short median survival
time ranging from 2-5 years, emphasizing the urgent need for effective treatments …

Idiopathic pulmonary fibrosis (IPF) is a form of chronic fibrosing interstitial lung disease of
unknown etiology and poor prognosis. The clinical course of IPF varies considerably in the …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease lacking a definite
etiology, characterized by the nonspecific symptoms of dyspnea and dry cough. Due to its …

1. Guo Y, Xiao L, Sun L, Liu F. Wnt/b-catenin signaling: a promising new target for fibrosis
diseases. Physiol Res 2012; 61: 337-346. 2. Konigshoff M, Kramer M, Balsara N, Wilhelm J …

Therefore, until high-quality, systematic data from reassessed patients are obtained from
registry efforts (eg, the Australian and European idiopathic pulmonary fibrosis registries), we …

Over the past year and a half, we have witnessed the emergence of prospective clinical trial
data on outcomes with RET-targeted therapy in patients with RET-rearranged lung cancers …

Objectives To test HRCT with either visual or quantitative analysis in both short-term and
long-term follow-up of stable IPF against long-term (transplant-free) survival, beyond 2 years …